

## Invega Sustenna® Quiz

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use? You would use a 1 and a half inch needle, a 22 gauge.
2. Name the most common side effects a patient may experience when taking Invega Sustenna®. Injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder
3. What black box warning is associated with this medication? BBW: increased mortality in elderly patients with dementia related psychosis
4. What is the recommended initial dosage for a person with a creatinine clearance of 65mL/min? \_\_\_\_\_ 156mg on treatment day one and 117 mg one week later, both administered in the deltoid muscle. Follow with monthly injections of 78 mg in either the deltoid or gluteal muscle.
5. What would the recommended maintenance dosage be for patient in #4? The maintenance dose given would be 78mg.
6. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®? A trial of oral paliperidone or oral risperidone is given to see how the patient will react while on this medication and to be able to develop a therapeutic treatment.
7. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure. Wash hands before drawing up and administering the medication. Use gloves before and during administration and drawing up the medication. Clean the injection site before administration of the injection.
8. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration. The patient has the right to what medications they choose to take or not. Without consent it is illegal to give any medication to the patient due to the fact that it goes against their right. They still have the right to withdrawal their consent of the medication up to the time of discharge of that particular admission stay.